Alkeus Pharmaceuticals Inc develops Gildeuretinol (ALK-001), an investigational therapy aimed at addressing the underlying mechanism of Stargardt disease, a genetic cause of blindness.
investor of
Metrics
marketPRIVATE
msh_idCOM:ALKEUSPHARMA
localeus
websitehttps://alkeuspharma.com/
source_ref359c8161-eb4b-4d23-bf7e-5e8881050394
products_or_servicesGildeuretinol (ALK-001) for the treatment of Stargardt disease and Geographic Atrophy associated with dry age-related macular degeneration.
United States